Carey Conley Thomson

Carey Conley Thomson

Auto-generated profile, based on publicly available information

Carey Conley Thomson

Mt Auburn Hospital, Pulmonary and Critical Care, Cambridge, Massachusetts, United States

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
GRGanesh Raghu
Ganesh Raghu
MRMartine Remy-Jardin
Martine Remy-Jardin
LRLuca Richeldi
Luca Richeldi
CTCarey C. Thomson
Carey C. Thomson
YIYoshikazu Inoue
Yoshikazu Inoue
KWKevin C. Wilson
Kevin C. Wilson
Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results: 1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions: The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians.

1 July 2025 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
APAnna J. Podolanczuk
Anna J. Podolanczuk
GHGary M. Hunninghake
Gary M. Hunninghake
KWKevin C. Wilson
Kevin C. Wilson
YKYet H. Khor
Yet H. Khor
FKFayez Kheir
Fayez Kheir
CRChristopher J. Ryerson
Christopher J. Ryerson
Background: There is growing interest in identifying early stages of interstitial lung disease (ILD) to improve patient outcomes. This document reviews updated evidence on interstitial lung abnormalities (ILAs); provides suggestions for screening, evaluation, and management; proposes criteria for distinguishing ILAs from ILD; and identifies research priorities. Methods: A committee of clinical and methodology experts met by video conference to define ILAs and ILD by consensus and voted on 11 prespecified questions after reviewing synthesized evidence from a systematic literature search. Agreement of ≥70% was required to approve each suggestion. Results: ILA is defined as nondependent bilateral parenchymal abnormalities on computed tomography, including ground-glass opacities or reticulations, lung distortion, traction bronchiectasis, and/or honeycombing involving ≥5% of a lung zone. The updated definition removes the prior exclusion of high-risk populations. ILD is distinguished from ILAs by symptoms (dyspnea/cough) attributable to an interstitial process, abnormal or declining lung function, fibrotic (honeycombing and/or reticulation with traction bronchiectasis involving ≥5% of total lung volume) or progressive imaging abnormalities, and/or specific fibrotic ILD patterns on imaging or pathology. Suggestions include ILA/ILD assessment on imaging acquired for lung cancer screening, screening adults with connective tissue disease and first-degree relatives of patients with familial pulmonary fibrosis, assessing baseline symptoms and pulmonary function among those with ILAs, and monitoring ILAs with chest computed tomography every 2–3 years. Conclusions: This document presents a comprehensive literature review of ILAs with updates to the Fleischner Society ILA definition, establishes a working ILD definition, and provides evidence-based suggestions for ILA evaluation and management.

1 November 2016 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
CCCharles S. Dela Cruz
Charles S. Dela Cruz
PLPatrick G. Lyons
Patrick G. Lyons
SPSusan Pasnick
Susan Pasnick
TWTanya Weinstock
Tanya Weinstock
PNPayam Nahid
Payam Nahid
CTCarey C. Thomson
Carey C. Thomson

1 March 2021 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
JOJeremy E. Orr
Jeremy E. Orr
JCJohn M. Coleman
John M. Coleman
JMJakob I. McSparron
Jakob I. McSparron
RORobert L. Owens
Robert L. Owens
MMMadalina Macrea
Madalina Macrea
CTCarey C. Thomson
Carey C. Thomson

1 April 2023 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
OOOmar Al Omari
Omar Al Omari
CJChinmay T. Jani
Chinmay T. Jani
AAAlaaeldin Ahmed
Alaaeldin Ahmed
HSHarpreet Singh
Harpreet Singh
ARAmr Radwan
Amr Radwan
UTUmit Tapan
Umit Tapan

15 March 2023 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
KSKatrina Steiling
Katrina Steiling
HKHasmeena Kathuria
Hasmeena Kathuria
CEChidiebere Peter Echieh
Chidiebere Peter Echieh
DODavid Ost
David Ost
MRM. Patricia Rivera
M. Patricia Rivera
JWJuan Wisnivesky
Juan Wisnivesky
Background: Lung nodules are common incidental findings, and timely evaluation is critical to ensure diagnosis of localized-stage and potentially curable lung cancers. Rates of guideline-concordant lung nodule evaluation are low, and the risk of delayed evaluation is higher for minoritized groups. Objectives: To summarize the existing evidence, identify knowledge gaps, and prioritize research questions related to interventions to reduce disparities in lung nodule evaluation. Methods: A multidisciplinary committee was convened to review the evidence and identify key knowledge gaps in four domains: 1) research methodology, 2) patient-level interventions, 3) clinician-level interventions, and 4) health system–level interventions. A modified Delphi approach was used to identify research priorities. Results: Key knowledge gaps included 1) a lack of standardized approaches to identify factors associated with lung nodule management disparities, 2) limited data evaluating the role of social determinants of health on disparities in lung nodule management, 3) a lack of certainty regarding the optimal strategy to improve patient–clinician communication and information transmission and/or retention, and 4) a paucity of information on the impact of patient navigators and culturally trained multidisciplinary teams. Conclusions: This statement outlines a research agenda intended to stimulate high-impact studies of interventions to mitigate disparities in lung nodule evaluation. Research questions were prioritized around the following domains: 1) need for methodologic guidelines for conducting research related to disparities in nodule management, 2) evaluating how social determinants of health influence lung nodule evaluation, 3) studying approaches to improve patient–clinician communication, and 4) evaluating the utility of patient navigators and culturally enriched multidisciplinary teams to reduce disparities.